Effects of Oral Pamidronate in Treatment of Primary Osteoporosis
일차성 골다공증 환자에서 경구 파미드로네이트의 치료효과
고, 보람; 김, 형일; 김, 연경; 안, 상미; 송, 경은; 정, 선혜; 김, 혜진; 김, 대중; 이, 관우; 정, 윤석
Journal of Korean Society of Osteoporosis, 3(1):62-66, 2005
Journal of Korean Society of Osteoporosis; 대한골다공증학회지
Objectives: Bisphosphonates are well-known agents for treatment of osteoporosis. Oral pamidronate treatment for osteoporosis were studied in Caucasian, but not in Korean. Effects of oral pamidronate were studied in Korean primary osteoporosis patients. Methods: Twenty four(11 men and 13 women) primary osteoporosis patients were treated with 100mg of daily pamidronate(panorin, Hanlim Co., Korea) for mean duration of 13.5±1.9months. Serum alkaline phosphatase, urine calcium/ creatinine ratio, bone mineral densities of spine(L1-4) and femur(neck, trochanter, ward, and total) were followed-up. Results: Serum alkaline phsophatase decreased from 95.3±28.0 to 69.4±23.1IU/L(P＜0.01). Urine calcium/creatinine ratio decreased from 0.132±0.076 to 0.083±0.052(P＜0.05). Bone mineral density of spine increased from 0.788±0.137 to 0.841±0.144g/cm2(P＜0.01). Bone mineral density of total proximal femur increased from 0.819±0.099 to 0.833±0.098g/cm2(P＜0.05). Conclusion: Oral pamidronate treatment for 1 year was effective in increasing bone mineral density and decreasing biochemical bone turnover rate. Further study of prospective randomized double blind trial will be needed.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
Total Visit :3,086,692
Total Download :1,259,515
Today View :745
Ajou University Medical Information & Media Center 164 Worldcup-ro Yeongtong-gu Suwon 16499 Korea / TEL : 031-219-5312 / FAX : 031-219-5314 Copyright (c) Ajou University Medical Information & Media Center All Rights Reserved. AJOU Open Repository는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.